Discovery Life Sciences is proud to announce its role as a Founding Member of the Organoid COMMONS — the Consortium for Organoid Manufacturing, Measurement, Optimization, and Network for Standards — and the appointment of Dr. Raluca Dumitru to its inaugural Governing Board.
The COMMONS brings together eight industry-leading organizations to establish global standards for iPSC-derived and donor-derived organoid development, manufacturing, and characterization. For Discovery Life Sciences, membership in this consortium reflects a natural extension of our core mission: providing the high-quality, well-characterized biological materials that researchers need to generate reliable, reproducible results. Our contribution centers on donor-derived biospecimens and our expanding tumoroid capabilities — tools increasingly critical for oncology drug discovery, toxicology testing, and cell and gene therapy development. As regulators and sponsors accelerate adoption of non-animal, human-relevant methodologies under the FDA Modernization Act, standardized donor-derived models are no longer optional — they are foundational.
As Dr. Raluca Dumitru put it: “Joining the Organoid COMMONS Governing Board reflects Discovery Life Sciences’ commitment to advancing human-relevant science that actually matters for patients.“
Read the full press release here, or contact our team to learn more about Discovery’s tumoroid services and biospecimen capabilities.
